ASN 2008
41st Annual Meeting of the American Society of Nephrology (ASN)
November 4th – 9th 2008, Philadelphia, USA
Video Selector
Once Monthly C.E.R.A. provides stable Hb levels in CKD patients on dialysis following direct switch from shorter acting ESAs (Poster number SA:PO2669)
- Dr Danilo Fliser
- ASN 2008
The safety profiles of ESAs at different hemoglobin levels (Poster number SA:PO2670)
- Dr Robert Provenzano
- ASN 2008
Erythrocyte survival, biology of erythropoiesis, Hb rise and decline
- Dr Tony Besarab
- Renal Academy
Post-transplant anaemia
- Dr Helio Tedesco Silva
- Renal Academy
Erythropoietin, cardiovascular biology and beyond
- Dr Pedro Aljama
- Renal Academy
C.E.R.A. has a comparable safety profile to other erythropoiesis stimulating agents (ESAs) in patients with chronic kidney disease (CKD)
- Dr Gilbert Deray
- EDTA 2008
C.E.R.A. maintains stable haemoglobin levels in dialysis patients regardless of administration route (IV or SC)
- Dr Bruce Spinowitz
- EDTA 2008
